AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2677862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 371316 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 43
Study 371316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 371316 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative perfusion scanning
Number of subjects: 43
Study 30933857 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after 3-month dual-antiplatelet therapy (DAPT)
Number of subjects: 2
Study 30933857 — intervention group
Group type: COMPARATOR
Intervention: 12-month ticagrelor-based DAPT
Number of subjects: 2
Study 30933857 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after 3-month DAPT
Number of subjects: 2
Study 28146136 — intervention group
Group type: EXPERIMENTAL
Intervention: Red meat consumption
Number of subjects: 1038
Study 28146136 — intervention group
Group type: COMPARATOR
Intervention: PUFA or PUFA-rich oils
Number of subjects: 1038
Study 28146136 — intervention group
Group type: COMPARATOR
Intervention: Soy intake
Number of subjects: 1038
Study 28146136 — intervention group
Group type: COMPARATOR
Intervention: Fish intake
Number of subjects: 1038
Study 25313429 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorblind diversity message
Number of subjects: 539
Study 25313429 — intervention group
Group type: COMPARATOR
Intervention: Multicultural diversity message
Number of subjects: 539
Study 23379922 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard or firm wire applied routinely on entry into transverse colon
Number of subjects: 112
Study 23379922 — intervention group
Group type: COMPARATOR
Intervention: Unaided colonoscope
Number of subjects: 112
Study 23379922 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard or firm wire
Number of subjects: 112
Study 20974598 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/day
Number of subjects: 330
Study 20974598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 18474737 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion tensor tractography analysis of fiber variables in patients with diffuse axonal injury.
Number of subjects: 12
Study 18474737 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted outcome scores from diffusion tensor tractography analysis.
Number of subjects: 12
Study 16583374 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with 0.2 mg/kg of alpha-galactosidase A (agalsidase-alfa) every 2 weeks for 6 months followed by 12 months of open-label ERT
Number of subjects: 25
Study 16583374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 14971605 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual interpretation of SPECT alone
Number of subjects: 90
Study 14971605 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual interpretation of both SPECT and 3D-SSP
Number of subjects: 90
Study 14971605 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated diagnosis based on 3D-SSP
Number of subjects: 90
Study 10994682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy integrated into Day Treatment Program (CBT/DTP)
Number of subjects: 24
Study 10994682 — intervention group
Group type: COMPARATOR
Intervention: Standard Day Treatment Program (DTP)
Number of subjects: 24
Study 10994682 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CBT/DTP and DTP)
Number of subjects: 24
Study 8651251 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3 induction therapy (5 mg/day IV for 10 to 14 days)
Number of subjects: 207
Study 8651251 — intervention group
Group type: COMPARATOR
Intervention: Conventional immunosuppressive regimen (CsA, azathioprine, prednisone)
Number of subjects: 207
Study 8651251 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3 induction therapy
Number of subjects: 207
Study 1616360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal salmon calcitonin
Number of subjects: 40
Study 1616360 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 40
Study 6085189 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin plus Thr28Nle31CCK25‐33 (continuous 6-day intravenous infusion)
Number of subjects: 9
Study 6085189 — intervention group
Group type: COMPARATOR
Intervention: FAM only (5-fluorouracil, adriamycin, and mitomycin C)
Number of subjects: 9
Study 31240605 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention and individual coaching
Number of subjects: 360
Study 30409942 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gums, used thrice daily for 2 weeks
Number of subjects: 20
Study 30409942 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP chewing gums, used thrice daily for 2 weeks
Number of subjects: 20
Study 25987491 — intervention group
Group type: COMPARATOR
Intervention: Combo (Passive + Dryland)
Number of subjects: 16
Study 25987491 — intervention group
Group type: COMPARATOR
Intervention: Dryland
Number of subjects: 16
Study 25987491 — intervention group
Group type: COMPARATOR
Intervention: Combo
Number of subjects: 16
Study 25123839 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban (intracoronary injection of 10 μg/kg prior to PCI, followed by intravenous infusion at 0.15 μg/kg min)
Number of subjects: 119
Study 25123839 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 119
Study 25123839 — intervention group
Group type: COMPARATOR
Intervention: Control (no tirofiban)
Number of subjects: 119
Study 23313205 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-core biopsy protocol (PB20 group)
Number of subjects: 339
Study 23313205 — intervention group
Group type: COMPARATOR
Intervention: 12-core biopsy protocol (PB12 group)
Number of subjects: 339
Study 23313205 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 339
Study 22013201 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye bran product (RP)
Number of subjects: 17
Study 22013201 — intervention group
Group type: COMPARATOR
Intervention: Refined white wheat product (WP)
Number of subjects: 17
Study 19043384 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial occlusion of the abdominal aorta by the NeuroFlo device
Number of subjects: 97
Study 19043384 — intervention group
Group type: COMPARATOR
Intervention: Conventional management of stroke patients
Number of subjects: 97
Study 16464718 — intervention group
Group type: EXPERIMENTAL
Intervention: MIBI scintigraphy in CHF patients
Number of subjects: 27
Study 16464718 — intervention group
Group type: COMPARATOR
Intervention: MIBI scintigraphy in healthy volunteers
Number of subjects: 27
Study 16464718 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of WR of MIBI with brain natriuretic peptide levels
Number of subjects: 27
Study 16464718 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of WR of MIBI with left ventricular ejection fraction
Number of subjects: 27
Study 16464718 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of WR of MIBI with WR of MIBG
Number of subjects: 27
Study 12649051 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention
Number of subjects: 304
Study 12649051 — intervention group
Group type: COMPARATOR
Intervention: Self‐test group
Number of subjects: 304
Study 12649051 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 304
Study 11450504 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg gliclazide (study 1)
Number of subjects: 7
Study 11450504 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg gliclazide after 2 months of therapy (80 mg t.i.d.)
Number of subjects: 7
Study 11450504 — intervention group
Group type: COMPARATOR
Intervention: Placebo (study 2)
Number of subjects: 7
Study 9240867 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine administration to mothers during prenatal and intrapartum periods, and to neonates for 6 weeks
Number of subjects: 0
Study 9240867 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 8159486 — intervention group
Group type: EXPERIMENTAL
Intervention: TempaDOT
Number of subjects: 172
Study 8159486 — intervention group
Group type: EXPERIMENTAL
Intervention: FirstTEMP
Number of subjects: 172
Study 8159486 — intervention group
Group type: COMPARATOR
Intervention: Glass mercury thermometer
Number of subjects: 172
Study 8159486 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature measurement sites
Number of subjects: 172
Study 3286041 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem 30 mg
Number of subjects: 11
Study 3286041 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 10 mg
Number of subjects: 11
Study 3286041 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 30 mg plus Nifedipine 10 mg
Number of subjects: 11
Study 3286041 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg with Diltiazem
Number of subjects: 11
Study 31957648 — intervention group
Group type: EXPERIMENTAL
Intervention: ERRT‐M
Number of subjects: 40
Study 31957648 — intervention group
Group type: COMPARATOR
Intervention: MCC
Number of subjects: 40
Study 29615136 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialogue-based psychosocial intervention (eight individual sessions of supported dialogues in their homes during the first six months following an acute stroke)
Number of subjects: 330
Study 29615136 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 330
Study 29615136 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialogue-based psychosocial intervention
Number of subjects: 330
Study 27159310 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulley exercises initiated 6 weeks postoperatively
Number of subjects: 53
Study 27159310 — intervention group
Group type: COMPARATOR
Intervention: Alternative rehabilitation program without pulleys
Number of subjects: 53
Study 25604640 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrihand
Number of subjects: 19
Study 25604640 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap & Track
Number of subjects: 19
Study 25604640 — intervention group
Group type: COMPARATOR
Intervention: GRAND (dietitian analysis)
Number of subjects: 19
Study 25245439 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamibarotene
Number of subjects: 269
Study 25245439 — intervention group
Group type: COMPARATOR
Intervention: ATRA
Number of subjects: 269
Study 23094271 — intervention group
Group type: EXPERIMENTAL
Intervention: Theobromine 100 mg/l for 5 min
Number of subjects: 24
Study 23094271 — intervention group
Group type: EXPERIMENTAL
Intervention: Theobromine 200 mg/l for 5 min
Number of subjects: 24
Study 23094271 — intervention group
Group type: COMPARATOR
Intervention: Control group (no theobromine treatment)
Number of subjects: 24
Study 20012076 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg)
Number of subjects: 60
Study 20012076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18831888 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover from enflurane to desflurane anaesthesia (group X)
Number of subjects: 46
Study 18831888 — intervention group
Group type: COMPARATOR
Intervention: Enflurane anaesthesia (group E)
Number of subjects: 46
Study 15947769 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 44
Study 15947769 — intervention group
Group type: COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 44
Study 11874389 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg meloxicam once
Number of subjects: 24
Study 11874389 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen three times daily
Number of subjects: 24
Study 11874389 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg diclofenac SR once
Number of subjects: 24
Study 10495460 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate zidovudine treatment
Number of subjects: 0
Study 10495460 — intervention group
Group type: COMPARATOR
Intervention: Deferred zidovudine treatment
Number of subjects: 0
Study 8930782 — intervention group
Group type: EXPERIMENTAL
Intervention: Befloxatone 5 mg
Number of subjects: 15
Study 8930782 — intervention group
Group type: EXPERIMENTAL
Intervention: Befloxatone 10 mg
Number of subjects: 15
Study 8930782 — intervention group
Group type: EXPERIMENTAL
Intervention: Befloxatone 20 mg
Number of subjects: 15
Study 8930782 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 50 mg
Number of subjects: 15
Study 8930782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1327933 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain rye bread (200-300 g/day)
Number of subjects: 12
Study 1327933 — intervention group
Group type: COMPARATOR
Intervention: Normal omnivorous diet
Number of subjects: 12
Study 1327933 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fiber wheat bread (200-300 g/day)
Number of subjects: 12
Study 1327933 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-meal wheat bread (200-300 g/day)
Number of subjects: 12
Study 1327933 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain rye bread
Number of subjects: 12
Study 1327933 — intervention group
Group type: COMPARATOR
Intervention: Control period (normal diet)
Number of subjects: 12
Study 1327933 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fiber wheat bread
Number of subjects: 12
Study 1327933 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-meal wheat bread
Number of subjects: 12
Study 3886305 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg alizapride/kg body weight
Number of subjects: 44
Study 3886305 — intervention group
Group type: COMPARATOR
Intervention: 0.6 mg domperidone/kg
Number of subjects: 44
Study 3886305 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment by investigator
Number of subjects: 44
Study 3886305 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 44
Study 30753650 — intervention group
Group type: COMPARATOR
Intervention: Acoustic enhancement of slow-wave activity (SWA) via 50 ms sounds phase-locked to slow-waves, with 5 s ON/5 s OFF stimulation
Number of subjects: 0
Study 30753650 — intervention group
Group type: COMPARATOR
Intervention: Acoustic enhancement of slow-wave activity (SWA)
Number of subjects: 0
Study 29419665 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) during decubitus position with limbs raised
Number of subjects: 31
Study 29419665 — intervention group
Group type: COMPARATOR
Intervention: Control protocol (decubitus position with limbs raised without NMES)
Number of subjects: 31
Study 26839992 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS Lateral Interbody Fusion (XLIF)
Number of subjects: 55
Study 26839992 — intervention group
Group type: COMPARATOR
Intervention: MIS Transforaminal Interbody Fusion (MIS TLIF)
Number of subjects: 55
Study 25354689 — intervention group
Group type: EXPERIMENTAL
Intervention: PRASE intervention (Patient Reporting and Action for a Safe Environment) which includes a 44-item questionnaire and a proforma for reporting safety incidents and positive experiences.
Number of subjects: 32
Study 25354689 — intervention group
Group type: EXPERIMENTAL
Intervention: PRASE intervention
Number of subjects: 32
Study 22954674 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice containing 6.51 g resistant starch daily
Number of subjects: 90
Study 20082714 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise therapy + usual care
Number of subjects: 81
Study 20082714 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) + usual care
Number of subjects: 81
Study 20082714 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 81
Study 19060577 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (TT) for 5 minutes on 3 consecutive days.
Number of subjects: 20
Study 19060577 — intervention group
Group type: COMPARATOR
Intervention: No Therapeutic Touch (NTT) for 5 minutes on 3 consecutive days.
Number of subjects: 20
Study 15821691 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Twin-block (TB) appliance
Number of subjects: 70
Study 15821691 — intervention group
Group type: COMPARATOR
Intervention: Modified Twin-block (MB) appliance
Number of subjects: 70
Study 12232494 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting (250 kcal; 3 l fluid intake/day) without mineral supplements (n = 103)
Number of subjects: 209
Study 12232494 — intervention group
Group type: COMPARATOR
Intervention: Fasting (250 kcal; 3 l fluid intake/day) with mineral supplements (3 x 2 to 3 x 3 Bullrich's Vital) (n = 106)
Number of subjects: 209
Study 10421283 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide withdrawal
Number of subjects: 20
Study 10421283 — intervention group
Group type: COMPARATOR
Intervention: Continuation of furosemide therapy
Number of subjects: 20
Study 7569764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 10
Study 7569764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1288904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride 2 mg.kg‐1 (Group B)
Number of subjects: 80
Study 1288904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine liquid 2 mg.kg‐1 (Group D)
Number of subjects: 80
Study 1288904 — intervention group
Group type: COMPARATOR
Intervention: Placebo liquid (Group A)
Number of subjects: 80
Study 1288904 — intervention group
Group type: COMPARATOR
Intervention: Placebo liquid (Group C)
Number of subjects: 80
Study 3908214 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing-scheme (adriamycin/cisplatinum–vincristine/cyclophosphamide–high dose methotrexate)
Number of subjects: 164
Study 3908214 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin/cyclophosphamide
Number of subjects: 164
Study 3908214 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin/cisplatinum
Number of subjects: 164
Study 3908214 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing-scheme
Number of subjects: 164
Study 31683779 — intervention group
Group type: EXPERIMENTAL
Intervention: P4 (dairy and vegetable protein blend)
Number of subjects: 14
Study 31683779 — intervention group
Group type: COMPARATOR
Intervention: Casein
Number of subjects: 14
Study 31683779 — intervention group
Group type: COMPARATOR
Intervention: Whey
Number of subjects: 14
Study 31683779 — intervention group
Group type: COMPARATOR
Intervention: Soy
Number of subjects: 14
Study 31683779 — intervention group
Group type: COMPARATOR
Intervention: Pea
Number of subjects: 14
Study 27785534 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific pre-contoured plate (case group)
Number of subjects: 21
Study 27785534 — intervention group
Group type: COMPARATOR
Intervention: Intra-operatively contoured plates (control group)
Number of subjects: 21
Study 27131984 — intervention group
Group type: EXPERIMENTAL
Intervention: Two short implants
Number of subjects: 23
Study 27131984 — intervention group
Group type: EXPERIMENTAL
Intervention: Three short implants
Number of subjects: 23
Study 27131984 — intervention group
Group type: EXPERIMENTAL
Intervention: Four short implants
Number of subjects: 23
Study 27131984 — intervention group
Group type: COMPARATOR
Intervention: Comparison among groups
Number of subjects: 23
Study 25316331 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Number of subjects: 450
Study 25316331 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 450
Study 22381164 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy in SES stratum (2,735 patients)
Number of subjects: 10221
Study 22381164 — intervention group
Group type: COMPARATOR
Intervention: Non-statin therapy in SES stratum (2,294 patients)
Number of subjects: 10221
Study 22381164 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy in BMS stratum (2,576 patients)
Number of subjects: 10221
Study 22381164 — intervention group
Group type: COMPARATOR
Intervention: Non-statin therapy in BMS stratum (2,616 patients)
Number of subjects: 10221
Study 21268411 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-Being Therapy (WBT)
Number of subjects: 162
Study 21268411 — intervention group
Group type: COMPARATOR
Intervention: Anxiety Management (AM)
Number of subjects: 162
Study 17879527 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese drugs combined with benazepril
Number of subjects: 108
Study 17879527 — intervention group
Group type: COMPARATOR
Intervention: Benazepril alone (Control)
Number of subjects: 108
Study 16219435 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol penetration-enhanced tetracaine gel (4% tetracaine in carbomer vehicle)
Number of subjects: 0
Study 16219435 — intervention group
Group type: COMPARATOR
Intervention: Non-penetration-enhanced tetracaine gel (4% tetracaine in carbomer vehicle)
Number of subjects: 0
Study 16219435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12114420 — intervention group
Group type: EXPERIMENTAL
Intervention: NSC 655649 single-dose format (step 1)
Number of subjects: 69
Study 12114420 — intervention group
Group type: EXPERIMENTAL
Intervention: NSC 655649 multiple-dose format (step 2)
Number of subjects: 69
Study 10051803 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (360 mg Mg/day)
Number of subjects: 11
Study 10051803 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 11
Study 7595698 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HD-MTX) with cranial radiation (CRT)
Number of subjects: 66
Study 7595698 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose methotrexate (CD-MTX)
Number of subjects: 66
Study 7595698 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (regardless of treatment)
Number of subjects: 66
Study 2405136 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25‐dihydroxyvitamin D3
Number of subjects: 82
Study 2405136 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydrotachysterol
Number of subjects: 82
Study 2405136 — intervention group
Group type: COMPARATOR
Intervention: Control period measurements
Number of subjects: 82
Study 419460 — intervention group
Group type: EXPERIMENTAL
Intervention: Debrisan (dextranomer)
Number of subjects: 50
Study 31742898 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg dapagliflozin
Number of subjects: 151
Study 31742898 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dapagliflozin
Number of subjects: 151
Study 31195337 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg
Number of subjects: 0